Clinical Trial

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2026-01-08; most recent amendment 2026-03-19.
Trial Details
NCT Number NCT07332000
Lead Sponsor Candel Therapeutics, Inc.
Conditions Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Enrollment 45 participants
Start Date 2025-10-30
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-20